TY - JOUR
T1 - Development of New Drugs for Autoimmune Hemolytic Anemia
AU - Xiao, Zhengrui
AU - Murakhovskaya, Irina
N1 - Publisher Copyright:
© 2022 by the authors. Licensee MDPI, Basel, Switzerland.
PY - 2022/5
Y1 - 2022/5
N2 - Autoimmune hemolytic anemia (AIHA) is a rare disorder characterized by the autoantibody-mediated destruction of red blood cells, and treatments for it still remain challenging. Traditional first-line immunosuppressive therapy, which includes corticosteroids and rituximab, is associated with adverse effects as well as treatment failures, and relapses are common. Subsequent lines of therapy are associated with higher rates of toxicity, and some patients remain refractory to currently available treatments. Novel therapies have become promising for this vulnerable population. In this review, we will discuss the mechanism of action, existing data, and ongoing clinical trials of current novel therapies for AIHA, including B-cell-directed therapy, phagocytosis inhibition, plasma cell-directed therapy, and complement inhibition.
AB - Autoimmune hemolytic anemia (AIHA) is a rare disorder characterized by the autoantibody-mediated destruction of red blood cells, and treatments for it still remain challenging. Traditional first-line immunosuppressive therapy, which includes corticosteroids and rituximab, is associated with adverse effects as well as treatment failures, and relapses are common. Subsequent lines of therapy are associated with higher rates of toxicity, and some patients remain refractory to currently available treatments. Novel therapies have become promising for this vulnerable population. In this review, we will discuss the mechanism of action, existing data, and ongoing clinical trials of current novel therapies for AIHA, including B-cell-directed therapy, phagocytosis inhibition, plasma cell-directed therapy, and complement inhibition.
KW - autoimmune hemolytic anemia
KW - autoimmune hemolytic anemia treatment
KW - cold agglutinin disease
KW - warm autoimmune hemolytic anemia
UR - http://www.scopus.com/inward/record.url?scp=85130520342&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85130520342&partnerID=8YFLogxK
U2 - 10.3390/pharmaceutics14051035
DO - 10.3390/pharmaceutics14051035
M3 - Review article
AN - SCOPUS:85130520342
SN - 1999-4923
VL - 14
JO - Pharmaceutics
JF - Pharmaceutics
IS - 5
M1 - 1035
ER -